Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 6/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.34 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4950984 | 0.98 | HTR1A (0.38) | HTR1AADRA2AADRA2BADRA2CADRA1D | |
| SCHEMBL4947512 | 0.95 | HTR1A (0.40) | HTR1AADRA2AADRA2BADRA2CADRA1D | |
| SCHEMBL4950562 | 0.91 | HTR1A (0.38) | HTR1AADRA2AADRA2BADRA2CADRA1D | |
| SCHEMBL4949450 | 0.90 | HTR1A (0.45) | HTR1AADRA2AADRA2BADRA2CADRA1D | |
| SCHEMBL4952031 | 0.89 | HTR1A (0.49) | HTR1AADRA2AADRA2BADRA2CADRA1D | |
| SCHEMBL4950310 | 0.87 | HTR1A (0.46) | HTR1AADRA2AADRA2BADRA2CADRA1D | |
| SCHEMBL4949709 | 0.85 | ADRA2A (0.48) | HTR1AADRA2AADRA2BADRA2CADRA1D | |
| SCHEMBL4945969 | 0.85 | HTR7 (0.39) | HTR1AHTR2AKEAP1NFE2L2 | |
| SCHEMBL4948343 | 0.84 | DRD3 (0.43) | HTR1AHTR2ADRD3 | |
| SCHEMBL4951024 | 0.83 | HTR1A (0.43) | HTR1AHTR2ADRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194539-A1 | Phenyl Diazepane Carboxamides and Annelated Phenyl Piperazine Carboxamides Containing Oxygen and Used as Dopamine D3 Antagonists | SCHWARZ PHARMA AG (DE) | 2008-08-14 | — | — | US | claimed |
| EP-1761524-B1 | PHENYL DIAZEPANE CARBOXAMIDES AND ANNELATED PHENYL PIPERAZINE CARBOXAMIDES CONTAINING OXYGEN AND USED AS DOPAMINE D3 ANTAGONISTS | SANOL ARZNEI SCHWARZ GMBH (DE) | 2007-11-21 | — | — | EP | claimed |
| US-20080194539-A1 | Phenyl Diazepane Carboxamides and Annelated Phenyl Piperazine Carboxamides Containing Oxygen and Used as Dopamine D3 Antagonists | SCHWARZ PHARMA AG (DE) | 2008-08-14 | — | — | US | disclosed |
| EP-1761524-B1 | PHENYL DIAZEPANE CARBOXAMIDES AND ANNELATED PHENYL PIPERAZINE CARBOXAMIDES CONTAINING OXYGEN AND USED AS DOPAMINE D3 ANTAGONISTS | SANOL ARZNEI SCHWARZ GMBH (DE) | 2007-11-21 | — | — | EP | disclosed |
| EP-1761524-A1 | PHENYL DIAZEPANE CARBOXAMIDES AND ANNELATED PHENYL PIPERAZINE CARBOXAMIDES CONTAINING OXYGEN AND USED AS DOPAMINE D3 ANTAGONISTS | SCHWARZ PHARMA AG (DE) | 2007-03-14 | — | — | EP | disclosed |
| WO-2006072430-A1 | PHENYL DIAZEPANE CARBOXAMIDES AND ANNELATED PHENYL PIPERAZINE CARBOXAMIDES CONTAINING OXYGEN AND USED AS DOPAMINE D3 ANTAGONISTS | SCHWARZ PHARMA AG (DE) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194539-A1 | Phenyl Diazepane Carboxamides and Annelated Phenyl Piperazine Carboxamides Containing Oxygen and Used as Dopamine D3 Antagonists | DRD3, DRD2, DRD1 | HTR1A 206/4885ADRA2A 95/4885ADRA2B 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.